Open letter on the future of research. Addition research to official title Commissioner Mariya Gabriel

The Scientific Committee is fully committed to a great mission: To increase and share the best clinical knowledge and the cutting-edge information from translational research in all neurological fields. Main actions are i) to facilitate exchanges and synergies with the Scientific Panels ii) to support the Guideline Production Group (update and diffusion of expertise and best clinical practice), iii) to interact positively with other scientific societies with reciprocal exchanges and liaise with the European Affairs sub-Committee to increase the awareness of Neurology in Europe.

In a recent article published in the August 2019 issue of the EAN Pages, we presented the framework based on which the collaboration between the EAN and the EFNR is currently unfolding. The Memorandum of Understanding between the two organizations, signed in 2017, is the guiding document that formally governs this partnership, which focuses on three key pillars for development: facilitating evidence-based clinical guideline production, promoting multidisciplinary education, and hosting joint sessions within the main scientific events organized annualy by these institutions. This article will focus on the latter priority for our collaboration, with the goal of disseminating relevant updates how our community benefits from the interaction between the EAN and the EFNR.

This month’s selected paper addresses the risk of neurological deficits in people with cavernomas treated with antithrombotic medication. Perhaps counter-intuitively, the authors report a lower risk of intracerebral haemorrhage in patients taking antithrombotic medication (mostly antiplatelet therapy). The study therefore provides reassurance for clinicians managing patients with this relatively common, and often incidental, vascular finding that antithrombotic therapy does not appear harmful; conversely, there could be some benefit, but this requires further evaluation in a randomised controlled trial.

Spain is the fourth-largest country in Europe, with a population of just more than 47 million, and is made up of mainland Spain, occupying the majority of the Iberian Peninsula, the Balearic islands in the Mediterranean, the cities of Ceuta and Melilla in North Africa, and the Canary Islands in the north-east Atlantic Ocean. Spain’s capital is Madrid, and the country is divided into 17 autonomous communities, which provide free, universal healthcare to all their inhabitants.

Abstract Submission for the Paris 2020 Congress is open!

Registration for the 6th EAN Congress in Paris, France, 23 May-26 May 2020, is now possible!

The  Portuguese Neurological Society has submitted its guidelines, which are now available for EAN Members in the Guideline Reference Center.

As part of the GBS|CIDP Foundation International’s mission to provide education and support research, it offers research grants to qualified applicants. Grants are made possible through the benevolence of many sources, including the Helen S. Manheimer Research Fund, contributions from individuals who have been personally touched by GBS or CIDP and by several commercial sources.

The 11th Regional Teaching Course (RTC) in sub-Saharan Africa (SSA) took place in Accra, Ghana. Dr. A. Charway Felli, President-elect of AFAN hosted the RTC held at the Ghana College of Physicians and Surgeons.

Clinical practice guidelines are a bridge between scientific evidence and real-world practice. This is the main reason why I decided to advance my background experience (in epidemiology, systematic reviews and meta-analyses), by working on guidelines. Because Neurology is my main… Continue Reading

Production of European standards of diagnosis, treatment and care within the various subfields of neurology, is one of the most important aims of EAN. EAN has therefore set-up a Guideline Production Group (GPG), to provide scientific assistance to active task forces and to oversee the work flow.

Zika virus circulation has decreased but there is a possibility of its emergence or re-emergence in all areas with competent mosquito vectors.

Levetiracetam and NOACs